Ranbaxy's Court Win On Lipitor Generics Leaves Compliance Issues Unanswered
This article was originally published in PharmAsia News
India's Ranbaxy Laboratories may have been freed to launch a U.S. generic of the world's best-selling drug if it gets U.S. FDA approval, but a court's action allowing it to do so failed to settle several issues roiling within the pharmaceutical industry
You may also be interested in...
Reports from Norway about deaths in very frail, elderly patients soon after receiving Pfizer/BioNTech’s COVID-19 jab have drawn regulatory scrutiny. Australia is looking at whether specific warnings about risks of vaccination in the very frail elderly or terminally ill should be included in the product information.
Viagra will soon be available OTC in Ireland following a successful switch, but patients will have to complete a mandatory consultation with a pharmacist before the ED treatment can be supplied.
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.